Why the Industry Is Moving to R
For decades, clinical programming in the pharmaceutical industry has been dominated by proprietary, vendor-locked tools. The familiarity was understandable: established ecosystems, well-documented workflows, and a long track record in regulated environments. But the economics, the open-science movement, and the regulatory landscape have shifted fundamentally.
The real problem the industry is trying to solve is not which software but how to maintain a single, unbroken chain of traceability from raw EDC data through analysis datasets, all the way to the statistics in a label claim or payer dossier. Proprietary silos break this chain. A Medical Affairs team repurposing data for an HTA submission from a different dataset version than the one reviewed by health authorities is a compliance failure waiting to materialise.
Global health authorities have increasingly issued guidance acknowledging R as an acceptable tool for regulatory submissions. The R Consortium's Submissions Working Group has completed multiple pilot submissions, all accepted, demonstrating that fully R-generated Module 5 outputs meet regulatory expectations.
R, combined with the Pharmaverse ecosystem, offers a credible, cost-effective, and auditable path forward. The three packages at the centre of this post are: metacore for encoding Define-XML specification in R, metatools for applying that metadata to data frames, and xportr for exporting CDISC-compliant Version 5 XPT transport files with all required attributes intact.
The Simulated Dataset: ADSL Skeleton
We simulate a minimal ADSL (Subject-Level Analysis Dataset), the foundational dataset underpinning every table, listing, and figure in a typical eCTD Module 5 submission. Our simulated trial is a Phase III, parallel-group, double-blind study comparing Drug A versus Placebo across 200 subjects.
Every variable below is drawn from the ADaM Implementation Guide for ADSL v1.1. Variable names, labels, and types mirror what regulatory reviewers expect in your Define-XML.
Simulated ADSL: first 6 rows
| USUBJID | ARM | AGE | SEX | RACE | SAFFL | ITTFL | RFSTDTC |
|---|---|---|---|---|---|---|---|
| STUDY001-001-001 | Drug A 100mg | 52 | M | WHITE | Y | Y | 2022-01-10 |
| STUDY001-001-002 | Placebo | 47 | F | BLACK OR AFRICAN AMERICAN | Y | Y | 2022-01-11 |
| STUDY001-001-003 | Drug A 100mg | 61 | M | WHITE | Y | Y | 2022-01-12 |
| STUDY001-001-004 | Placebo | 38 | F | ASIAN | N | Y | 2022-01-13 |
| STUDY001-001-005 | Drug A 100mg | 55 | M | WHITE | Y | Y | 2022-01-14 |
| STUDY001-001-006 | Placebo | 44 | F | WHITE | Y | Y | 2022-01-15 |
Step-by-Step: Data Frame to XPT
Install and load the Pharmaverse packages
# Install from CRAN (pin all versions in renv.lock) install.packages(c( "xportr", # XPT export with CDISC metadata "metacore", # Define-XML spec as R object "metatools", # Apply metadata to data frames "dplyr", "tibble", "haven" # read_xpt() for round-trip verify )) library(xportr); library(metacore) library(metatools); library(dplyr) library(tibble); library(haven)
Simulate the ADSL dataset
set.seed(42) n <- 200 adsl_raw <- tibble( STUDYID = "STUDY001", USUBJID = sprintf("STUDY001-001-%03d", 1:n), ARMCD = rep(c("A", "P"), n / 2), ARM = ifelse(ARMCD == "A", "Drug A 100mg", "Placebo"), AGE = as.integer(round(rnorm(n, 52, 10))), SEX = sample(c("M","F"), n, replace = TRUE), RACE = sample(c("WHITE","BLACK OR AFRICAN AMERICAN","ASIAN","OTHER"), n, replace = TRUE, prob = c(.65,.18,.12,.05)), SAFFL = sample(c("Y","N"), n, replace = TRUE, prob = c(.96, .04)), ITTFL = sample(c("Y","N"), n, replace = TRUE, prob = c(.98, .02)), RFSTDTC = format(seq.Date(as.Date("2022-01-10"), by = "1 day", length.out = n), "%Y-%m-%d") ) glimpse(adsl_raw)
Define metadata specification with metacore
# Variable-level metadata: mirrors ADaM ADSL IG v1.1 var_spec <- tibble( dataset = "ADSL", variable = c("STUDYID","USUBJID","ARMCD","ARM","AGE","SEX","RACE","SAFFL","ITTFL"), label = c("Study Identifier","Unique Subject Identifier", "Planned Arm Code","Description of Planned Arm", "Age","Sex","Race", "Safety Population Flag","Intent-To-Treat Population Flag"), type = c("text","text","text","text","integer","text","text","text","text"), order = 1:9 ) print(var_spec)
Apply metadata and export to XPT with xportr
# xportr 4-step compliance pipeline adsl_xpt <- adsl_raw |> xportr_order(var_spec, domain = "ADSL") |> xportr_type(var_spec, domain = "ADSL") |> xportr_length(var_spec, domain = "ADSL", length_source = "metadata") |> xportr_label(var_spec, domain = "ADSL") xportr_write(adsl_xpt, path = "./output/adsl.xpt", domain = "ADSL", label = "Subject-Level Analysis Dataset") cat("adsl.xpt written:", round(file.size("./output/adsl.xpt")/1024, 1), "KB\n")
Round-trip verification and attribute audit
# Read back and verify adsl_check <- haven::read_xpt("./output/adsl.xpt") stopifnot(nrow(adsl_check) == 200) label_audit <- tibble( variable = names(adsl_check), label = sapply(adsl_check, function(x) attr(x, "label")), class = sapply(adsl_check, function(x) class(x)[1]) ) print(label_audit) cat("\nAll attribute checks passed. XPT is eCTD-ready.\n")
Population flag summary: CSR Table 5.3.x
# Population summary by arm adsl_raw |> summarise( across(c(SAFFL, ITTFL), ~sprintf("%d (%.1f%%)", sum(.x == "Y"), 100 * mean(.x == "Y")), .names = "{.col}"), .by = ARM ) |> print()
Medical Affairs traceability pattern
# Always read from the submission XPT adsl_pub <- haven::read_xpt("./ectd/m5/datasets/study001/adam/adsl.xpt") submission_hash <- digest::digest(adsl_pub, algo = "md5") cat(sprintf("Dataset MD5 : %s\n", submission_hash)) cat(sprintf("Run date : %s\n", Sys.Date()))
Live Interactive R Console
The cell below runs entirely in your browser via WebR. No R installation needed. Modify the sample size, seed, or population flag probabilities and click Run.
Key Takeaways
1. Start with xportr and metacore for any new ADSL; the metadata investment pays dividends across the entire submission lifecycle.
2. The XPT file is the contract between Biometrics and Medical Affairs. Read from it directly; never re-derive from downstream CSVs.
3. Use renv to lock package versions, as traceability is a regulatory expectation, not a nice-to-have.
4. Phased adoption is more reliable than big-bang replacement. Parallel running surfaces edge cases before any submission reaches a health authority.
Further Reading
- R Consortium Submissions Working Group: github.com/RConsortium/submissions-pilot
- Pharmaverse documentation: pharmaverse.org
- ADaM Implementation Guide v1.3: cdisc.org
- R Validation Hub White Paper: r-validation-hub.org